CliniMACS System

DEVICE3 trials

Sponsors

Ginna Laport, St. Jude Children's Research Hospital

Conditions

Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk FactorsAcute Myeloid LeukemiaChronic Lymphocytic Leukemia (CLL) - RefractoryChronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic PhaseHematologic MalignancyHematopoietic Cell TransplantationMyelodysplastic Syndrome (MDS) - High and Intermediate RiskNon-Hodgkin's Lymphoma (NHL)

Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

RecruitingNCT07257419

St. Jude Children's Research HospitalHematologic Malignancy, Hematopoietic Cell Transplantation, Relapsed Pediatric ALL

Start: 2026-03-03End: 2035-12-01Target: 60Updated: 2026-03-10

Phase 2

Haploid Allogeneic Transplant Using the CliniMACS System

TerminatedNCT00185679

Ginna LaportAcute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Lymphocytic Leukemia (CLL) - Refractory, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase +2

Start: 2001-11-30End: 2010-02-28Updated: 2015-03-09

Unknown Phase

Natural Killer (NK) Cell Transplantation for AML

CompletedNCT00187096

St. Jude Children's Research HospitalAcute Myeloid Leukemia

Start: 2005-09-30End: 2013-03-31Updated: 2014-06-19